Development Stage

In 2018, as part of its VIPE strategy, Abingworth led a private placement for Soleno, a publicly traded Californian company conducting a Phase 3 clinical trial of a potential treatment for Prader-Willi Syndrome, a rare inherited disease whose symptoms include an incessant craving for food that is highly disruptive for patients and their families. Abingworth then participated in three subsequent secondary offerings to support the company including a successful randomized withdrawal clinical trial which culminated the approval by the FDA of Soleno’s product, Vykat XR, the first approved treatment for PWS. The company was acquired by Neurocrine Biosciences in May 2026.

In February 2025, Abingworth co-led a US$112m Series C financing for AdvanCell, a clinical-stage radiopharmaceutical company focused on delivering alpha-emitting radionuclides specifically to the sites of tumors. This financing funded the advancement into Phase 2 of the company’s lead product for metastatic prostate cancer, ADVC001, which targets PSMA to deliver alpha-emitting lead-212 to tumor sites. In July 2026, Abingworth also participated in a $315m Series D financing to fund advancement of ADVC001 toward Phase 3 and expansion of manufacturing and other capabilities.